Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Adults With Cystic Fibrosis

Details

Therapeutic category
Restore CFTR Function
Trial status
closed Participating Centres
Phase
Phase II

Full title

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808 in Healthy Adult Subjects and in Adults With Cystic Fibrosis

In this study, the investigational CFTR modulator medicine PTI-808 will be given in combination with one or two other investigational modulator medicines, PTI-801 and PTI-428. PTI-428, PTI-801, and PTI-808 are considered cystic fibrosis transmembrane conductance regulator (CFTR) modulators being developed to treat the underlying cause of cystic fibrosis. PTI-428 is a CFTR amplifier that increases the amount of CFTR protein in the cell, PTI-801 is a CFTR corrector that improves the processing of CFTR protein in the cell, and PTI-808 is a CFTR potentiator to enhance the activity of CFTR at the cell surface. Modulators on their own have been shown to have limited activity, and it is predicted that combining modulators will be necessary to address CFTR defects. There is a screening visit up to 4 weeks before the active portion of the study, which lasts 4 weeks. In the active portion of the study, participants will take one of the following: PTI-808 by mouth in combination with PTI-801 and PTI-428, PTI-808 in combination with PTI-801 and placebo, or all placebos for 4 weeks. The study medication is taken once a day at breakfast. Two weeks after stopping the study medication, another visit will occur.
Trial Reference Number
124674
Trial type
Medication
Intervention
CFTR Modulators
Last edited date
31/01/2020
CF sponsor
Proteostasis Therapeutics, Inc.
CF sponsor type
Commercial

Who can take part?

Age
18+
Top inclusion criteria
  • Homozygous for the F508del mutation (have 2 copies of F508del) or who are heterozygous for the F508del mutation (have only 1 copy of F508del)
  • FEV1 between 40-90%
Top exclusion criteria
  • Participation in another clinical trial or treatment with an investigational agent
  • History of organ transplantation.

Your donation will make a difference:

Select amount